Table 3. The pattern and causes of dose adjustment.

Categories	Lazertinib (n=103), n (%)
No. of dose adjustment due to adverse events	39 (37.9)
Last adjusted dose of lazertinib
160 mg per day	20 (19.4)
≥80 and <160 mg per day	9 (8.7)
Final discontinuation following dose reduction	6 (5.8)
Discontinuation without prior dose reduction	4 (3.9)
Adverse events leading to dose reduction without discontinuation, n (%)	29 (28.2)
Paresthesia	17 (16.5)
Rash	3 (2.9)
Fatigue	3 (2.9)
Dizziness	2 (1.9)
Weight loss	2 (1.9)
Anorexia	2 (1.9)
Headache	1 (1.0)
Urticaria	1 (1.0)
Pneumonitis	1 (1.0)
Acneform dermatitis	1 (1.0)
Adverse events leading to permanent discontinuation, n (%)	10 (9.7)
Paresthesia	5 (4.9)
Rash	2 (1.9)
Fatigue	2 (1.9)
Diarrhea	2 (1.9)
Bilirubin elevation	1 (1.0)
Pneumonitis	1 (1.0)
Nausea	1 (1.0)
Anorexia	1 (1.0)
Dizziness	1 (1.0)